Coronavirus (COVID-19) News
Filter News
Found 2,564 articles
-
Aethlon Medical Receives Ethics Board Approval to Add Second Site to its Ongoing Clinical Trial of its Hemopurifier® to Treat Severe COVID-19 in India
5/22/2023
Aethlon Medical, Inc. announced that it has received Ethics Review Board approval from the Maulana Azad Medical College, for a second site for its ongoing clinical trial of Aethlon's Hemopurifier® to treat severe COVID-19 in India.
-
Access to Novavax's COVID Vaccine Grows with Extended Interim Authorization for Adolescents in Singapore
5/12/2023
Novavax, Inc. announced that the Singapore Health Sciences Authority has granted extended interim authorization and the Ministry of Health has included Nuvaxovid™ into the National Vaccination Programme as a non-mRNA option for adolescents aged 12 through 17 for active immunization to prevent COVID.
-
Grifols Launches AlphaID™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic COPD
5/11/2023
Grifols announced it has launched its AlphaID™ At Home Genetic Health Risk Service, the first-ever free direct-to-consumer program in the U.S., to screen for the genetic risk of alpha1-antitrypsin deficiency.
-
Nagasaki University Presented Results Of a Specified Clinical Trial On The Use of L. lactis strain Plasma For Patients With COVID-19
5/11/2023
Nagasaki University presented the results of a specified clinical trial on patients with COVID-19 using Lactococcus.
-
Sleep Apnea Associated with Increased Risk for Long COVID
5/11/2023
Sleep apnea may significantly increase the risk for long COVID in adults, according to a study led by the National Institutes of Health's RECOVER Initiative and supported by NYU Langone Health as home to the effort's Clinical Science Core.
-
SINOVAC’s CoronaVac® Answers Hong Kong’s Need for Self-Pay COVID-19 Vaccines
5/10/2023
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced it will provide its inactivated COVID-19 vaccine, CoronaVac®, to self-paying groups in Hong Kong.
-
The layoffs come as the company posts nearly $300 million in net losses and just over $80 million in revenue during the first quarter of 2023. -
Positive Phase 2 Topline Results Show Novavax's COVID-Influenza Combination, Stand-alone Influenza and High-dose COVID Vaccine Candidates Demonstrate Robust Immune Responses
5/9/2023
Novavax, Inc. announced that its COVID-Influenza Combination, stand-alone influenza and high-dose COVID vaccine candidates all showed a reassuring preliminary safety profile as well as comparable reactogenicity to individual Novavax influenza and COVID vaccine candidates or authorized influenza vaccine comparators.
-
Biophytis has Requested a Pre-Submission Meeting with the EMA for the Marketing Authorisation of Sarconeos (BIO101) for the Treatment of COVID-19
5/9/2023
Biophytis SA announced that it has filed for a pre-submission meeting request with the European Medicine Agency to discuss filing for conditional Marketing Authorisation in Europe for Sarconeos in the treatment of severe form of COVID-19.
-
University of Missouri Laboratory for Infectious Disease Study Finds Technology Used in Widely Deployed Fingerprint Scanners Kills The Virus that Causes COVID-19
5/9/2023
Researchers at the University of Missouri Laboratory for Infectious Disease Research released the results of a study indicating that electroluminescent film technology, found in widely deployed biometric fingerprint scanners, actively kills SARS-CoV-2.
-
The German biotech is trying to deepen its pipeline in cancer and other infectious diseases as COVID-19 markets contract and the international public health emergency comes to an end. -
Hyundai Bioscience announced positive phase 2 clinical study results of the global blockbuster candidate for the COVID-19 antiviral drug
5/3/2023
Hyundai Bioscience announced on the 28th that it had received the clinical study report for the COVID-19 phase 2 clinical trial of its antiviral drug 'Xafty'.
-
Revive Therapeutics Announces Data Safety Monitoring Board Meeting Date on Phase 3 Clinical Study of Bucillamine in the Treatment of COVID-19
5/2/2023
Revive Therapeutics Ltd. announced that the independent Data and Safety Monitoring Board meeting of the Bucillamine Phase 3 clinical trial for COVID-19 is expected to convene on May 10th, 2023 and will assess the efficacy of Bucillamine in the Study’s Post-Dose selection data under the current Study’s protocol primary endpoint, the proportion of patients meeting a composite endpoint of hospitalization or death from time of first dose through Day 28 following randomization.
-
Bioxytran Interview at the Emerging Growth Conference 2023
5/1/2023
BIOXYTRAN, INC. announced that Bioxtran CCO Michael Sheikh will be discussing the medical and scientific communities’ reaction to the latest peer reviewed journal article on the Emerging Growth Conference on May 3, 2023 at 12:35 pm EST.
-
Veristat Congratulates HIPRA for EMA Approval of Its BIMERVAX® COVID-19 Vaccine
4/25/2023
Veristat congratulated HIPRA for marketing authorization by the European Medicines Agency and European Commission of BIMERVAX®, a bivalent adjuvanted vaccine based on the Beta and Alpha variants of SARS-CoV-2 and indicated as a booster dose for people over 16 years of age.
-
NanoViricides is Expanding its Broad-Spectrum Antiviral Program to Explore Further Antiviral Applications of its COVID Clinical Drug Ingredient
4/25/2023
NanoViricides, Inc. reports that it is exploring additional antiviral applications for NV-387, the active pharmaceutical ingredient used in NV-CoV-2, the Company's COVID clinical drug candidate.
-
NanoViricides Has Shipped Drug Products for Impending Clinical Trials of NV-CoV-2, Its COVID Drug Candidate
4/17/2023
NanoViricides, Inc., a clinical stage global leader in nanomedicines against viruses, announced that it has shipped the drug products for impending clinical trials of NV-CoV-2, its COVID drug candidate, to its collaborator, Karveer Meditech Pvt. Ltd., Kolhapur, India.
-
Atea Announces Presentation of Bemnifosbuvir Data Demonstrating Reduced Hospitalizations for COVID-19 Patients at 2023 European Congress of Clinical Microbiology & Infectious Diseases
4/12/2023
71% reduction in risk of hospitalization for mild to moderate COVID-19 outpatients treated with bemnifosbuvir versus placebo in MORNINGSKY study, regardless of vaccination status
-
At the World Vaccine Congress this week, Novavax presented data suggesting that its protein nanoparticle booster generated immune responses that could protect against severe infection. -
The FDA has granted emergency use authorization to InflaRx’s vilobelimab, now to be marketed as Gohibic, for hospitalized adult patients with COVID-19, the German biotech announced Tuesday.